Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Price:
10.1 USD
-1.37%
Market Closed
Updated:
May 9, 2024
Phathom Pharmaceuticals Inc
Research & Development
|
Phathom Pharmaceuticals Inc
Research & Development Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
Research & Development
-$49.9m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-378%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$15.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.6B
|
CAGR 3-Years
-74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$29.5B
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-15%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$9.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-6%
|
See Also
What is Phathom Pharmaceuticals Inc's Research & Development?
Research & Development
-49.9m
USD
-49.9m
USD
Based on the financial report for Dec 31, 2023, Phathom Pharmaceuticals Inc's Research & Development amounts to -49.9m USD.
What is Phathom Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-378%
-378%
Over the last year, the Research & Development growth was 30%. The average annual Research & Development growth rates for Phathom Pharmaceuticals Inc have been 20% over the past three years , -378% over the past five years .
You don't have any saved screeners yet
